Cassava Sciences: simufilam shows stable ADAS-Cog in mild Alzheimer's over 24 months

FILANA THERAPEUTICS, INC.

Mild Alzheimer's patients on continuous simufilam (n=47) averaged 0.07 point ADAS-Cog change (±1.51 SE) from baseline to month 24.
Non-continuous mild group (n=40) declined 1.04 points on ADAS-Cog (±1.65 SE); largest separation during placebo withdrawal.
Moderate Alzheimer's patients on continuous simufilam (n=32) declined 11.05 points on ADAS-Cog (±1.91 SE).
Simufilam 100 mg twice daily safe and well tolerated; no drug-related serious adverse events; common TEAEs were COVID-19 and UTI.
Phase 3 top-line results expected: 52-week study year-end 2024; 76-week study mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.